Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (ILMN), a global leader in genomic sequencing technologies, provides critical tools advancing precision medicine and life science research. This dedicated news hub offers investors and industry professionals centralized access to official press releases, financial disclosures, and strategic updates directly from the company.
Track developments across key areas including quarterly earnings, sequencing platform innovations, and global health partnerships. Stay informed about regulatory milestones, product launches, and collaborations shaping the future of genomic analysis. Bookmark this page for unfiltered access to Illumina's latest announcements, enabling data-driven decisions in the rapidly evolving biotechnology sector.
Illumina, Inc. (NASDAQ: ILMN) will participate in the RBC 2024 Global Healthcare Conference on May 14, 2024, with a fireside chat at 5:30am Pacific Time. The webcast can be accessed on the company's website, with a replay available for 30 days post-event.
Illumina reported financial results for Q1 2024, with core revenue at $1.06 billion, a 2% decrease from Q1 2023. GAAP operating margin was 11.0% and non-GAAP operating margin was 20.6%. Revenue decreased by 1% to $1.08 billion. GAAP diluted loss per share was ($0.79), while non-GAAP diluted earnings per share were $0.09. Illumina aims to divest GRAIL by end of Q2 2024, with a funding commitment of $1 billion in a capital markets transaction.
In celebration of DNA Day, Illumina in Cambridge, United Kingdom, hosted 150 students for hands-on science activities, inspiring young scientists to pursue careers in STEM. HRH The Princess Royal visited the event, emphasizing the importance of genomics and STEM education. The Future Is Bright initiative, promoting global genomic literacy, engages 100,000 learners annually, aiming to reach 5 million by 2030.